Joint Meeting of the Dental Products Panel of the Medical Devices Advisory Committee of the Center for Devices and Radiological Health and the Peripheral and Central Nervous System Drugs Advisory Committee of the Center for Drug Evaluation and Research; Notice of Meeting, 16582-16583 [E6-4760]
Download as PDF
<![CDATA[
16582
Federal Register / Vol. 71, No. 63 / Monday, April 3, 2006 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Administration for Children and
Families
Advisory Committee on Immunization
Practices: Meeting
Notice for April 2006 Advisory
Committee Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following Federal
Committee meeting.
Name: Advisory Committee on
Immunization Practices (ACIP).
Times and Dates: 8 a.m.–7 p.m., June 29,
2006; 8 a.m.–6 p.m., June 30, 2006.
Place: Centers for Disease Control and
Prevention, 1600 Clifton Road, NE., Building
19, Room 232, Atlanta, Georgia 30333.
Additional Information: In order to
expedite the security clearance process at the
CDC Clifton Road Campus, all ACIP
attendees are now required to register on-line
at https://www.cdc.gov/nip/acip, which can
be found under the ‘‘Upcoming Meetings’’
tab. Please be sure to complete all the
required fields before submitting your
registration.
Please Note: All non-U.S. citizens who
have not pre-registered by June 2, 2006 will
not be allowed access to the campus and will
not be allowed to register on site. All non
U.S. Citizens are required to complete the
‘‘Access Request Form’’ and register on line
at https://www.cdc.gov/nip/acip. The access
request form can be obtained by contacting
Demetria Gardner at (404) 639–8836 and
should be e-mailed directly to Ms. Gardner
upon completion to dgardner@cdc.gov.
For Further Information Contact: Demetria
Gardner, Epidemiology and Surveillance
Division, National Immunization Program,
CDC, 1600 Clifton Road, NE., (E–61), Atlanta,
Georgia 30333, telephone (404) 639–8096, fax
(404) 639–8616.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
wwhite on PROD1PC61 with NOTICES
Dated: March 28, 2006.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E6–4775 Filed 3–31–06; 8:45 am]
BILLING CODE 4163–18–P
VerDate Aug<31>2005
17:30 Mar 31, 2006
Jkt 208001
Office of Planning, Research
and Evaluation, ACF, DHHS.
ACTION: Notice of meeting; Advisory
Committee on Head Start Accountability
and Educational Performance Measures.
AGENCY:
SUMMARY: The Secretary of Health and
Human Services, by authority of 42
U.S.C. 9836A, section 641A(b) of the
Head Start Act, as amended (5 U.S.C.
Appendix 2), has formed the Advisory
Committee on Head Start
Accountabilit5y and Educational
Performance Measures (the Committee).
The committee is governed by the
provisions of Public Law 92–463, as
amended (5 U.S.C. Appendix 2).
The function of the Committee is to
help assess the progress of HHS in
developing and implementing
educational measures in the Head Start
Program. This includes the Head Start
National Reporting System (NRS). The
Committee is to provide
recommendations for integrating NRS
with other ongoing assessments of the
effectiveness of the program. The
Committee will make recommendations
as to how NRS and other assessment
data can be included in the broader
Head Start measurement efforts found in
the Family and Child Experiences
Survey (FACES), the National Head
Start Impact Study, Head Start’s
Performance Based Outcome System,
and the ongoing evaluation of the Early
Head Start program.
DATES: April 24, 2006, 8:30 a.m.–5 p.m.
(Dinner Recess). April 25, 2006, 8:30
a.m.–5 p.m.
Place: Residence Inn Bethesda
Downtown, 7335 Wisconsin Avenue,
Bethesda, MD 20814.
Agenda: The Committee will hear
presentations related to existing Head
Start evaluations and NRS
implementation and will continue the
discussions begun at the previous
Committee meetings in 2005.
There will be a period set aside for
public comments on April 24, 2006,
from 10:30 a.m. to 11:30 a.m. Persons
wishing to speak at the meeting must
limit their comments to three minutes,
but may also provide the Committee
with supplementary written materials.
Those wishing to speak at the meeting
must sign up upon arrival at the
meeting, and comments will be heard
on a first come, first served basis until
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
the comment period is filled.
Approximately 15 speakers can be
accommodated. If not all present can be
accommodated during the presentation
period, persons may submit written
statements or papers to be considered by
the Committee at a later time. On-site
registration for those wishing to
comment will open at 8 a.m. on April
24, 2006.
SUPPLEMENTARY INFORMATION: This
meetings is open to the public. Persons
wishing to bring written statements or
papers focused on relevant, existing
research with Head Start populations or
on measures appropriate for low-income
four- and five-year old children are
welcome to do so. Individuals may also
e-mail such documents to
Secretaryadvisory-hs@esi-de.com of
mail to: ESI, ATTN: Townley Knudson,
Head Start Secretary’s Advisory
Committee, 7735 Old Georgetown Road,
Suite 600, Bethesda, MD 20814.
Documents received shall be
presented to the Committee. The
Committee meeting records shall be
kept at the Aerospace Center located at
901 D Street, SW., Washington, DC
20447. Information related to this
meeting will be available on the Head
Start Web site https://www.acf.hhs.gov/
programs/hsb/budget/AdvCmteSep05/
index.htm.
An interpreter for the deaf and hard
of hearing will be available upon
advance request by contacting
Secretaryadvisory-hs@esi-dc.com.
Naomi Goldstein,
Director, Office of Planning, Research and
Evaluation, Administration for Children and
Families.
[FR Doc. 06–3152 Filed 3–31–06; 8:45 am]
BILLING CODE 4184–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Joint Meeting of the Dental Products
Panel of the Medical Devices Advisory
Committee of the Center for Devices
and Radiological Health and the
Peripheral and Central Nervous
System Drugs Advisory Committee of
the Center for Drug Evaluation and
Research; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
E:\FR\FM\03APN1.SGM
03APN1
wwhite on PROD1PC61 with NOTICES
Federal Register / Vol. 71, No. 63 / Monday, April 3, 2006 / Notices
Names of Committees: The Dental
Products Panel of the Medical Devices
Advisory Committee of the Center for
Devices and Radiological Health (CDRH)
and the Peripheral and Central Nervous
System Drugs Advisory Committee of
the Center for Drug Evaluation and
Research (CDER). This will be a joint
meeting of the two committees.
General Function of the Joint
Committee: To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on September 6 and 7, 2006, from
8 a.m. to 5 p.m.
Location: Holiday Inn, Walker/
Whetstone Rm., Two Montgomery
Village Ave., Gaithersburg, MD.
Contact Person: Michael E. Adjodha,
Center for Devices and Radiological
Health (HFZ–480), Food and Drug
Administration, 9200 Corporate Blvd.,
Rockville, MD 20850, 301–827–5283,
ext. 123, e-mail:
Michael.adjodha@fda.hhs.gov or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572) in the
Washington, DC area), code
3014512518. Please call the Information
Line for up-to-date information on this
meeting.
Agenda: This joint committee will
review and discuss peer-reviewed
scientific literature on dental amalgam
devices. Dental amalgam, also called
‘‘encapsulated amalgam,’’ consists of
dental mercury and amalgam alloys.
This joint committee will review and
discuss peer-reviewed scientific
literature on dental amalgam and its
potential mercury toxicity, specifically
as it relates to neurotoxic effects. Certain
consumer groups have raised concerns
about the effects of using mercury as a
component of dental restorative
materials; therefore, we are combining
the expertise of the Dental Products
Panel of the Medical Device Advisory
Committee with the neurology expertise
of the Peripheral and Central Nervous
System Drugs Advisory Committee.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person by August 23, 2006. On
September 6 and 7, 2006, oral
presentations from the public will be
scheduled at the beginning of committee
deliberations and near the end of the
deliberations. Time allotted for each
presentation may be limited. Those
VerDate Aug<31>2005
17:30 Mar 31, 2006
Jkt 208001
desiring to make formal oral
presentations should submit written
notification to the contact person by
August 23, 2006, and include the names
and addresses of proposed participants,
and an indication of the approximate
time requested to make their
presentation.
Persons attending FDA’s advisory
committee meetings are advised that we
are not responsible for providing access
to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Ann Marie
Williams, Conference Management
Staff, 240–276–0450 ext. 113, at least 7
days in advance of the meeting.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: March 22, 2006.
Scott Gottlieb,
Deputy Commissioner for Policy.
[FR Doc. E6–4760 Filed 3–31–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–5037–N–16]
Screening and Eviction for Drug Abuse
and Other Criminal Activity
Office of the Chief Information
Officer, HUD
ACTION: Notice.
AGENCY:
SUMMARY: The proposed information
collection requirement described below
has been submitted to the Office of
Management and Budget (OMB) for
review, as required by the Paperwork
Reduction Act. The Department is
soliciting public comments on the
subject proposal.
Public Housing Agencies may request
criminal records from any law
enforcement agency concerning an adult
applying for admission to a public
housing or Section 8 program and may
deny admission to, or evict those who
engage in criminal activity.
DATES: Comments Due Date: May 3,
2006
Interested persons are
invited to submit comments regarding
this proposal. Comments should refer to
ADDRESSES:
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
16583
the proposal by name and/or OMB
approval Number (2577–0232) and
should be sent to: HUD Desk Officer,
Office of Management and Budget, New
Executive Office Building, Washington,
DC 20503; fax: 202–395–6974.
FOR FURTHER INFORMATION CONTACT:
Lillian Deitzer, Reports Management
Officer, AYO, Department of Housing
and Urban Development, 451 Seventh
Street, SW., Washington, DC 20410; email Lillian Deitzer at
Lillian_L_Deitzer@HUD.gov or
telephone (202) 708–2374. This is not a
toll-free number.
Copies of available documents
submitted to OMB may be obtained
from Ms. Deitzer.
SUPPLEMENTARY INFORMATION: This
notice informs the public that the
Department of Housing and Urban
Development has submitted to OMB a
request for approval of the information
collection described below. This notice
is soliciting comments from members of
the public and affecting agencies
concerning the proposed collection of
information to: (1) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (2) Evaluate the
accuracy of the agency’s estimate of the
burden of the proposed collection of
information; (3) Enhance the quality,
utility, and clarity of the information to
be collected; and (4) Minimize the
burden of the collection of information
on those who are to respond; including
through the use of appropriate
automated collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
This notice also lists the following
information:
Title of Proposal: Screening and
Eviction for Drug Abuse and other
Criminal Activity.
OMB Approval Number: 2577–0232.
Form Numbers: None.
Description of the Need For the
Information and Its Proposed Use:
Public Housing Agencies may request
criminal records from any law
enforcement agency concerning an adult
applying for admission to a public
housing or Section 8 program and may
deny admission to, or evict those who
engage in criminal activity.
Frequency of Submission: On
occasion.
E:\FR\FM\03APN1.SGM
03APN1
]]>Agencies
[Federal Register Volume 71, Number 63 (Monday, April 3, 2006)]
[Notices]
[Pages 16582-16583]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-4760]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Joint Meeting of the Dental Products Panel of the Medical Devices
Advisory Committee of the Center for Devices and Radiological Health
and the Peripheral and Central Nervous System Drugs Advisory Committee
of the Center for Drug Evaluation and Research; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
[[Page 16583]]
Names of Committees: The Dental Products Panel of the Medical
Devices Advisory Committee of the Center for Devices and Radiological
Health (CDRH) and the Peripheral and Central Nervous System Drugs
Advisory Committee of the Center for Drug Evaluation and Research
(CDER). This will be a joint meeting of the two committees.
General Function of the Joint Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on September 6 and 7, 2006,
from 8 a.m. to 5 p.m.
Location: Holiday Inn, Walker/Whetstone Rm., Two Montgomery Village
Ave., Gaithersburg, MD.
Contact Person: Michael E. Adjodha, Center for Devices and
Radiological Health (HFZ-480), Food and Drug Administration, 9200
Corporate Blvd., Rockville, MD 20850, 301-827-5283, ext. 123, e-mail:
Michael.adjodha@fda.hhs.gov or FDA Advisory Committee Information Line,
1-800-741-8138 (301-443-0572) in the Washington, DC area), code
3014512518. Please call the Information Line for up-to-date information
on this meeting.
Agenda: This joint committee will review and discuss peer-reviewed
scientific literature on dental amalgam devices. Dental amalgam, also
called ``encapsulated amalgam,'' consists of dental mercury and amalgam
alloys. This joint committee will review and discuss peer-reviewed
scientific literature on dental amalgam and its potential mercury
toxicity, specifically as it relates to neurotoxic effects. Certain
consumer groups have raised concerns about the effects of using mercury
as a component of dental restorative materials; therefore, we are
combining the expertise of the Dental Products Panel of the Medical
Device Advisory Committee with the neurology expertise of the
Peripheral and Central Nervous System Drugs Advisory Committee.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person by August 23,
2006. On September 6 and 7, 2006, oral presentations from the public
will be scheduled at the beginning of committee deliberations and near
the end of the deliberations. Time allotted for each presentation may
be limited. Those desiring to make formal oral presentations should
submit written notification to the contact person by August 23, 2006,
and include the names and addresses of proposed participants, and an
indication of the approximate time requested to make their
presentation.
Persons attending FDA's advisory committee meetings are advised
that we are not responsible for providing access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Ann Marie Williams,
Conference Management Staff, 240-276-0450 ext. 113, at least 7 days in
advance of the meeting.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: March 22, 2006.
Scott Gottlieb,
Deputy Commissioner for Policy.
[FR Doc. E6-4760 Filed 3-31-06; 8:45 am]
BILLING CODE 4160-01-S
